Diagnosis: Type 2 diabetes above target with moderately increased albuminuria

Key differentials and contributing factors

• Medication nonadherence
• Dietary or activity changes
• Glucocorticoid exposure
• Intercurrent infection
• Progressive beta-cell dysfunction
• Other causes of albuminuria

Key investigations

• Repeat HbA1c at an appropriate interval
• Repeat urine albumin-to-creatinine ratio
• eGFR and electrolytes
• Lipid profile
• Retinal assessment
• Foot and neuropathy examination
• Cardiovascular-risk assessment

Treatment principles

• Individualized glycemic target
• Diabetes self-management education
• Metformin when appropriate
• SGLT2 inhibitor and/or GLP-1–based therapy according to cardiorenal and weight considerations
• Blood-pressure and lipid management
• Kidney, retinal and foot monitoring

Nutrition and lifestyle

• Individualized eating pattern
• Reduced refined carbohydrates
• Adequate dietary fibre
• Weight-management support
• Resistance and aerobic activity as tolerated

Botanical safety: Never substitute a botanical glucose-lowering product for insulin or necessary prescription treatment.

Clinical Pearl: Cardiorenal benefits may influence medication selection independently of the HbA1c-lowering effect.

NPLEX Trap: A single elevated urinary albumin result should be interpreted clinically and usually confirmed, but it should not be ignored.

Reference basis: ADA Standards of Care in Diabetes—2026 emphasize individualized therapy and use of agents with demonstrated kidney and cardiovascular benefits in patients with relevant comorbidities.

Diagnosis: Persistent hypertension aggravated by glycyrrhizin-containing licorice

Key investigations

• Validated office and home blood-pressure measurements
• Electrolytes and renal function
• Urinalysis or urine albumin assessment
• Glucose or HbA1c
• Lipid profile
• ECG when indicated
• Secondary-cause evaluation when appropriate

Treatment principles

• Stop or reduce contributing substances
• Confirm adherence and measurement technique
• Lifestyle treatment
• Appropriate combination pharmacotherapy
• Monitor renal function and electrolytes
• Assess overall cardiovascular risk

Botanical safety: Licorice is especially concerning in hypertension, heart failure, kidney disease, edema, hypokalemia and patients using digoxin, diuretics or corticosteroids.

Clinical Pearl: Always ask specifically about teas, candies, chewing tobacco and traditional products containing licorice.

NPLEX Trap: “Natural” licorice is not the same as deglycyrrhizinated licorice and may cause clinically important hypertension.

Reference basis: The 2025 Hypertension Canada guideline supports validated measurement, lifestyle treatment for all patients and pharmacotherapy according to blood-pressure level and cardiovascular risk.

Diagnosis: Primary-prevention dyslipidemia with multiple cardiovascular-risk factors

Key investigations

• Repeat fasting or nonfasting lipid assessment when appropriate
• Blood pressure
• Diabetes screening
• Liver enzymes before treatment when indicated
• TSH when secondary dyslipidemia is suspected
• Medication and alcohol review
• Cardiovascular-risk calculation
• Lipoprotein(a) or apoB in selected patients

Treatment principles

• Smoking cessation
• Dietary improvement
• Regular physical activity
• Statin therapy according to risk
• Assess adherence and LDL-C response
• Add evidence-based nonstatin treatment when goals are not reached in appropriate high-risk patients

Nutrition

• Reduce trans fat and excess saturated fat
• Emphasize vegetables, legumes, whole grains, nuts and appropriate unsaturated fats
• Increase soluble fibre
• Address excess refined carbohydrate and alcohol when triglycerides are elevated

Clinical Pearl: A patient can have high cardiovascular risk despite having no cardiovascular symptoms.

NPLEX Trap: Red yeast rice should not automatically be treated as a harmless food supplement.

Reference basis: The 2026 ACC/AHA multisociety dyslipidemia guidance retains statins as foundational therapy and incorporates individualized LDL-C goals, risk assessment and selective coronary-calcium testing.

Diagnosis: Overt primary hypothyroidism caused by Hashimoto thyroiditis

Key differentials

• Iron-deficiency anemia
• Major depression
• Sleep apnea

• Medication effects
• Central hypothyroidism
• Adrenal insufficiency
• Chronic kidney or liver disease

Key investigations

• TSH and free T4
• Thyroid antibodies when relevant
• CBC and ferritin when anemia is suspected
• Lipid profile
• Sodium and renal function
• Pregnancy testing when applicable
• Adrenal evaluation when clinically indicated

Treatment principles

• Levothyroxine replacement
• Consistent medication timing
• Reassess TSH after dosage changes
• Avoid overtreatment
• Adjust promptly during pregnancy
• Investigate persistent symptoms despite biochemical control

Nutrition and supplements: Routine high-dose iodine is not indicated in autoimmune hypothyroidism.

Clinical Pearl: Biotin supplements can interfere with some thyroid laboratory assays and should be specifically documented.

NPLEX Trap: Do not interpret low free T4 with an inappropriately normal TSH as uncomplicated primary hypothyroidism; consider central disease.

Reference basis: The American Thyroid Association identifies levothyroxine as standard replacement therapy and emphasizes appropriate monitoring and individualized treatment.

Diagnosis: Uncomplicated GERD

Key differentials

• Acute coronary syndrome
• Peptic ulcer disease
• Functional heartburn
• Eosinophilic esophagitis
• Esophageal motility disorder
• Biliary disease
• Medication-induced esophagitis

Alarm features

• Dysphagia or odynophagia
• Gastrointestinal bleeding
• Iron-deficiency anemia
• Persistent vomiting
• Unintentional weight loss
• Progressive symptoms

Treatment principles

• Weight management when relevant
• Avoid meals shortly before lying down
• Elevate the head of the bed for nocturnal symptoms
• PPI therapy when indicated
• Use the lowest effective maintenance strategy
• Investigate refractory or alarm symptoms

Pharmacology safety: Review NSAIDs, bisphosphonates, potassium tablets and other medications that may cause upper-GI injury.

Clinical Pearl: Improvement with antacid does not reliably exclude a cardiac cause of chest discomfort.

NPLEX Trap: Do not send every uncomplicated reflux patient directly for endoscopy, but do not overlook alarm symptoms.

Reference basis: ACG guidance supports empiric PPI therapy for typical uncomplicated GERD and diagnostic evaluation when alarm or refractory features are present.

Diagnosis: IBS-D, a disorder of gut-brain interaction

Key differentials

• Celiac disease

• Inflammatory bowel disease
• Microscopic colitis
• Lactose or other carbohydrate intolerance
• Medication-induced diarrhea
• Chronic infection
• Hyperthyroidism
• Bile-acid diarrhea

Alarm features

• Rectal bleeding
• Unintentional weight loss
• Nocturnal symptoms
• Iron-deficiency anemia
• Fever
• Abdominal mass
• New onset at an older age
• Significant family history

Management principles

• Positive clinical diagnosis when appropriate
• Limited targeted testing
• Therapeutic relationship and education
• Symptom-directed dietary and pharmacologic treatment
• Address anxiety, sleep and stress when relevant
• Avoid repeated unnecessary investigations

Clinical Pearl: IBS can be diagnosed positively; it does not always require exhaustive testing by exclusion.

NPLEX Trap: Do not diagnose IBS when unexplained bleeding, anemia, weight loss or nocturnal diarrhea is present.

Reference basis: ACG guidance supports a positive diagnostic strategy, celiac testing in IBS-D and selected use of dietary and peppermint-oil interventions.

Diagnosis: Symptomatic knee osteoarthritis

Key differentials

• Inflammatory arthritis
• Crystal arthritis
• Meniscal injury
• Septic arthritis
• Referred hip pain
• Lumbar radiculopathy
• Osteonecrosis

Key assessments

• Pain pattern
• Functional impairment
• Joint examination
• Gait
• Muscle strength
• Medication and fall-risk review

Management principles

• Education and self-management
• Exercise
• Weight management
• Topical or oral medication according to risk
• Assistive devices when indicated
• Intra-articular treatment in selected patients
• Surgical referral for severe refractory disease

Physical medicine: Avoid high-force techniques directly through an acutely inflamed, unstable or recently injured joint.

Clinical Pearl: The severity of radiographic findings does not always correlate with pain severity.

NPLEX Trap: Routine inactivity accelerates weakness and functional decline; appropriately prescribed movement is treatment.

Reference basis: ACR/Arthritis Foundation guidance strongly emphasizes exercise, weight management and appropriate use of topical NSAIDs in knee osteoarthritis.

Diagnosis: Chronic primary low-back pain without neurologic compromise

Red flags

• New urinary retention or incontinence
• Saddle anesthesia
• Progressive weakness
• Fever or immunosuppression
• Significant trauma
• Cancer history
• Unexplained weight loss
• Osteoporosis or prolonged corticosteroid use
• Severe unremitting night pain

Management principles

• Reassurance without dismissing symptoms
• Maintain normal activity
• Progressive exercise
• Ergonomic and occupational assessment
• Cognitive-behavioural strategies when appropriate
• Judicious medication use
• Avoid low-value imaging and passive-treatment dependence

Physical-medicine safety: High-velocity manipulation is inappropriate when fracture, malignancy, infection, cauda equina syndrome, major instability or severe neurologic compromise is suspected.

Clinical Pearl: Degenerative findings on MRI are common in people without pain.

NPLEX Trap: Chronic pain does not automatically indicate structural instability or a need for imaging.

Reference basis: WHO recommends holistic, person-centred, non-surgical care for chronic primary low-back pain and supports combinations of education, exercise and selected psychological or physical interventions.

Diagnosis: Inadequately controlled asthma without a current severe exacerbation

Key assessments

• Symptom frequency
• Night awakening
• Reliever use
• Activity limitation
• Exacerbation history
• Inhaler technique
• Adherence
• Smoking or vaping
• Occupational and allergen exposure
• Comorbid rhinitis, reflux and obesity

Treatment principles

• Confirm the diagnosis
• Use ICS-containing treatment
• Correct inhaler technique
• Provide a written action plan
• Address modifiable exposures
• Review response after treatment adjustment
• Escalate promptly for severe symptoms

Clinical Pearl: A normal oxygen saturation between exacerbations does not indicate adequate asthma control.

NPLEX Trap: Do not prescribe long-acting beta₂-agonist monotherapy for asthma.

Reference basis: The 2026 GINA strategy incorporates current evidence for diagnosis, assessment and ICS-containing treatment rather than SABA-only asthma care.

Diagnosis: Major depressive disorder with passive suicidal ideation requiring structured risk assessment

Key differentials

• Bipolar depression
• Grief
• Adjustment disorder
• Substance-induced mood disorder
• Hypothyroidism
• Anemia
• Medication adverse effects
• Sleep disorder
• Trauma-related disorder

Key assessments

• Suicide and self-harm risk
• History of mania or hypomania
• Psychosis
• Substance use
• Functional impairment
• Medical contributors
• Social support and safety
• Baseline symptom scale when useful

Treatment principles

• Safety assessment and planning
• Collaborative treatment selection
• Cognitive-behavioural, interpersonal or behavioural-activation therapy
• Antidepressant pharmacotherapy when appropriate
• Measurement-based follow-up
• Monitor adherence, adverse effects and activation
• Continue treatment after remission according to recurrence risk

Botanical safety: St. John’s wort has extensive interactions with antidepressants, contraceptives, anticoagulants, transplant medication, HIV medication and other therapies.

Clinical Pearl: Always screen for previous mania or hypomania before treating an apparent unipolar depressive episode.

NPLEX Trap: Passive suicidal statements are not “low risk” by definition; they require direct assessment.

Reference basis: CANMAT’s 2023 adult major-depression guideline emphasizes comprehensive assessment, collaborative treatment selection and evidence-based psychological, pharmacological and neurostimulation options.

Diagnosis: Stable COPD with moderate airflow obstruction and recurrent exacerbations

Key differentials

• Asthma
• Heart failure
• Bronchiectasis
• Interstitial lung disease
• Lung cancer
• Chronic pulmonary infection

Key investigations

• Post-bronchodilator spirometry
• Oxygen saturation
• CBC when anemia or polycythemia is suspected
• Chest imaging when clinically indicated
• Alpha-1 antitrypsin assessment in appropriate patients

• Exacerbation history and symptom scoring

Treatment principles

• Smoking cessation
• Long-acting inhaled bronchodilator treatment
• Inhaler-technique assessment
• Pulmonary rehabilitation
• Vaccination
• Exacerbation-prevention strategy
• Oxygen only when established criteria are met

Clinical Pearl: Inhaled corticosteroid monotherapy is not standard COPD treatment.

NPLEX Trap: Do not diagnose COPD from symptoms or smoking history without spirometric confirmation.

Reference basis: The 2026 GOLD report continues to base COPD diagnosis on post-bronchodilator airflow obstruction and recommends individualized treatment based on symptoms and exacerbation risk.

Diagnosis: CKD G3a with albuminuria and potentially harmful NSAID exposure

Key investigations

• Serial eGFR
• Urine albumin-to-creatinine ratio
• Electrolytes and bicarbonate
• CBC
• Calcium and phosphate when indicated
• Urinalysis
• Kidney ultrasound when structural disease is suspected
• Cardiovascular-risk assessment

Treatment principles

• Control blood pressure
• Optimize diabetes treatment
• Continue kidney-protective medication when tolerated
• Avoid nephrotoxins
• Adjust medications for kidney function

• Assess cardiovascular risk
• Refer for rapid decline, severe albuminuria, resistant hypertension, unexplained hematuria, or advanced disease

Nutrition: Sodium, protein, potassium, and phosphate advice should be individualized.

Clinical Pearl: A normal serum creatinine does not necessarily indicate normal kidney function.

NPLEX Trap: Do not recommend “kidney detoxification” herbs to a patient with CKD.

Reference basis: KDIGO defines CKD by abnormalities lasting more than three months and emphasizes cause, GFR category, albuminuria, medication safety, cardiovascular protection, and risk-based monitoring.

Diagnosis: MASLD associated with diabetes, obesity, hypertension, and dyslipidemia

Key differentials

• Alcohol-associated liver disease
• Viral hepatitis
• Autoimmune hepatitis
• Medication-induced liver injury
• Hemochromatosis
• Wilson disease
• Biliary disease

Key investigations

• Liver enzymes
• CBC and platelets
• Viral hepatitis testing
• Metabolic profile
• FIB-4 or another validated fibrosis score
• Elastography when indicated
• Additional etiologic testing based on presentation

Treatment principles

• Weight management
• Regular physical activity

• Diabetes treatment
• Dyslipidemia and blood-pressure management
• Avoid hepatotoxic substances
• Specialist referral for suspected advanced fibrosis

Clinical Pearl: The degree of ALT elevation does not reliably indicate fibrosis severity.

NPLEX Trap: Normal or mildly elevated liver enzymes do not exclude advanced fibrosis.

Reference basis: AASLD guidance emphasizes cardiometabolic management and noninvasive fibrosis-risk assessment rather than relying on aminotransferase elevation alone.

Key differentials

• Medication-induced constipation
• Hypothyroidism
• Hypercalcemia
• Colorectal malignancy
• Pelvic-floor dysfunction
• Neurologic disease
• Irritable bowel syndrome with constipation

Alarm features

• Rectal bleeding
• Iron-deficiency anemia
• Unintentional weight loss
• New severe symptoms
• Abdominal mass
• Persistent vomiting
• Significant family history

Treatment principles

• Review medications
• Gradually increase fibre when appropriate
• Consider psyllium
• Use osmotic or stimulant laxatives appropriately
• Evaluate refractory cases for defecatory disorders
• Use pelvic-floor biofeedback when indicated

Clinical Pearl: More fibre can worsen discomfort in some patients with severe bloating or pelvic-floor dysfunction.

NPLEX Trap: Do not prescribe fibre alone when bowel obstruction is suspected.

Reference basis: Joint AGA–ACG guidance supports fibre, polyethylene glycol, magnesium oxide in suitable patients, and selected stimulant or prescription agents for chronic idiopathic constipation.

Key differentials

• Transient ischemic attack
• Retinal disease
• Seizure
• Cluster headache
• Subarachnoid hemorrhage
• Intracranial mass
• Medication-overuse headache

Key assessments

• Aura characteristics
• Headache frequency and disability
• Neurologic examination
• Medication and contraceptive history
• Pregnancy status
• Cardiovascular contraindications
• Red flags for secondary headache

Treatment principles

• Trigger and headache diary
• Appropriate acute treatment
• Preventive treatment when attacks are frequent or disabling
• Avoid medication overuse
• Reconsider estrogen-containing contraception
• Address sleep, hydration, regular meals, and stress

Integrative care: Magnesium or riboflavin may be discussed for prevention in selected patients, but dosing, kidney function, interactions, and adverse effects require review.

Clinical Pearl: Migraine aura usually develops gradually; abrupt negative neurologic deficits require evaluation for vascular disease.

NPLEX Trap: Do not assume every visual disturbance in a migraine patient is a benign aura.

Diagnosis: Iron-deficiency anemia secondary to heavy menstrual bleeding

Key differentials

• Thalassemia

• Anemia of chronic inflammation
• Gastrointestinal blood loss
• Malabsorption
• Pregnancy-associated iron deficiency
• Bleeding disorder

Key investigations

• CBC and ferritin
• Reticulocyte count when indicated
• Pregnancy testing
• Gynecologic assessment
• Evaluation for uterine pathology
• Coagulation or bleeding-disorder assessment when appropriate
• Gastrointestinal assessment based on age and clinical features

Treatment principles

• Oral or intravenous iron according to severity and tolerance
• Treat the source of blood loss
• Recheck hemoglobin and iron stores
• Continue replacement long enough to replenish stores
• Urgent assessment for hemodynamic instability or severe symptoms

Clinical Pearl: Ferritin may be falsely normal or high during inflammation.

NPLEX Trap: Do not attribute iron deficiency to menstruation without considering gastrointestinal or other blood loss when clinically indicated.

Reference basis: ACOG advises that heavy menstrual bleeding be assessed for anemia, including iron stores, and that the underlying cause of bleeding be evaluated.

Key secondary causes

• Glucocorticoid exposure
• Hyperthyroidism
• Hyperparathyroidism
• Malabsorption
• Hypogonadism
• Chronic kidney or liver disease
• Multiple myeloma

Key investigations

• DXA
• CBC
• Calcium
• Creatinine

• Vitamin D
• TSH
• Additional testing for secondary causes
• Vertebral imaging when indicated

Treatment principles

• Fracture-risk assessment
• Bisphosphonate or another appropriate agent
• Calcium primarily from diet when possible
• Correct vitamin D deficiency
• Weight-bearing and resistance exercise
• Fall prevention
• Periodic reassessment

Clinical Pearl: Osteoporosis is usually asymptomatic until a fracture occurs.

NPLEX Trap: Calcium supplementation alone is not sufficient treatment for established high-risk osteoporosis.

Reference basis: The Bone Health and Osteoporosis Foundation clinician guide addresses diagnosis, secondary-cause assessment, fracture prevention, exercise, nutrition, and pharmacologic treatment.

Key differentials

• Prostate cancer
• Urethral stricture
• Bladder dysfunction
• Urinary infection
• Medication effects
• Neurogenic bladder
• Diabetes-related polyuria

Key investigations

• Symptom assessment
• Digital rectal examination
• Urinalysis
• Creatinine when indicated
• Postvoid residual

• PSA following shared decision-making
• Imaging or urodynamic testing in selected cases

Treatment principles

• Reduce evening fluids when appropriate
• Review decongestants and anticholinergic medications
• Alpha-blocker
• 5-alpha-reductase inhibitor for appropriate prostate enlargement
• Combination treatment when indicated
• Procedural treatment for complications or refractory symptoms

Clinical Pearl: BPH does not cause prostate cancer, but the two conditions can coexist.

NPLEX Trap: Do not assume every older man with urinary symptoms has uncomplicated BPH.

Reference basis: NIDDK describes BPH as nonmalignant prostate enlargement that may cause urinary obstruction and bladder, urinary-tract, or kidney complications.

Key differentials

• Allergic contact dermatitis
• Irritant dermatitis
• Psoriasis
• Scabies
• Tinea
• Cutaneous lymphoma in atypical disease

Treatment principles

• Gentle bathing
• Fragrance-free moisturizer
• Trigger reduction
• Topical corticosteroids
• Topical calcineurin or other nonsteroidal agents when appropriate
• Treatment of secondary infection only when present
• Systemic treatment for selected moderate-to-severe disease

Clinical Pearl: Pruritus often precedes visible worsening of the rash.

NPLEX Trap: Routine topical antibiotics and antiseptics are not indicated for every eczema flare.

Reference basis: Updated AAD guidelines strongly recommend moisturizers, topical corticosteroids, calcineurin inhibitors, and selected nonsteroidal topical treatments, while discouraging routine topical antimicrobial treatment.

Key assessments

• Lesion duration
• Angioedema
• Airway symptoms
• Medication triggers
• Physical triggers

• Systemic symptoms
• Photographs of lesions
• Limited targeted laboratory investigation

Treatment principles

• Second-generation H1 antihistamine
• Dose escalation when appropriate
• Specialist referral for refractory disease
• Omalizumab in selected patients
• Short corticosteroid rescue only in exceptional severe episodes
• Avoid chronic systemic corticosteroids

Clinical Pearl: Most chronic spontaneous urticaria is not caused by a food allergy.

NPLEX Trap: Antihistamines do not replace epinephrine when anaphylaxis is present.

Reference basis: Chronic urticaria guidance supports nonsedating H1 antihistamines as first-line therapy and allows supervised dose escalation for inadequate control.

Key differentials

• Viral rhinitis
• Nonallergic rhinitis
• Chronic rhinosinusitis
• Medication-induced rhinitis
• Structural nasal obstruction

Treatment principles

• Allergen reduction
• Saline irrigation
• Intranasal corticosteroid
• Intranasal or oral antihistamine
• Combination intranasal therapy when needed
• Immunotherapy for selected patients
• Review for coexisting asthma

Clinical Pearl: Nasal itching strongly supports an allergic mechanism.

NPLEX Trap: Routine food-allergy testing is not indicated for uncomplicated allergic rhinitis.

Reference basis: The AAAAI rhinitis practice parameter identifies intranasal corticosteroids as preferred monotherapy for persistent allergic rhinitis and supports intranasal antihistamine combinations when needed.

Key differentials

• Pregnancy
• Thyroid disease
• Hyperprolactinemia
• Nonclassic congenital adrenal hyperplasia
• Cushing syndrome
• Androgen-secreting tumour
• Hypothalamic amenorrhea

Treatment principles

• Lifestyle and weight-neutral health goals
• Menstrual-cycle protection
• Management of acne and hirsutism
• Metformin for selected metabolic indications
• Fertility treatment when desired
• Screening for diabetes, dyslipidemia, sleep apnea, anxiety, and depression

Clinical Pearl: Polycystic-appearing ovaries are not required when the other diagnostic features are present.

NPLEX Trap: Do not diagnose PCOS without excluding pregnancy and important endocrine mimics.

Reference basis: The 2023 international evidence-based guideline provides comprehensive recommendations for reproductive, metabolic, dermatologic, fertility, and psychological aspects of PCOS.

Key assessments

• Bleeding history
• Pregnancy possibility
• Cardiovascular and thrombotic history
• Breast-cancer risk
• Liver disease
• Osteoporosis risk
• Genitourinary symptoms
• Medication interactions

Treatment principles

• Shared decision-making
• Hormone therapy for appropriate candidates
• Nonhormonal prescription options
• Vaginal moisturizers and lubricants
• Local vaginal therapy when indicated
• Sleep and lifestyle support
• Investigation of postmenopausal bleeding

Clinical Pearl: Any new vaginal bleeding after menopause requires evaluation.

NPLEX Trap: Do not prescribe systemic estrogen alone to a patient with an intact uterus unless there is a specific protective strategy.

Reference basis: The Menopause Society outlines hormone and evidence-based nonhormone options for vasomotor symptoms and cautions that many complementary products lack reliable effectiveness or quality evidence.

Key differentials

• Genitourinary syndrome of menopause
• Vaginitis
• Sexually transmitted infection
• Interstitial cystitis
• Urolithiasis
• Urinary retention
• Bladder malignancy

Treatment principles

• Confirm symptomatic infections
• Use the narrowest appropriate antimicrobial
• Avoid unnecessary treatment of asymptomatic bacteriuria
• Consider vaginal estrogen after menopause
• Discuss patient-initiated or prophylactic strategies when appropriate
• Investigate hematuria, stones, obstruction, or atypical infections

Clinical Pearl: Persistent urinary symptoms with negative cultures require reconsideration of the diagnosis.

NPLEX Trap: Do not treat a positive urine culture in an asymptomatic nonpregnant patient automatically.

Reference basis: The 2025 AUA/CUA/SUFU recurrent-UTI guideline emphasizes culture documentation, antimicrobial stewardship, vaginal estrogen after menopause, and individualized preventive strategies.

Key differentials

• Obstructive sleep apnea
• Restless-legs syndrome
• Depression or anxiety
• Bipolar disorder
• Substance effects
• Medication-induced insomnia
• Circadian-rhythm disorder

Treatment principles

• CBT-I
• Consistent wake time
• Stimulus control
• Sleep-window restriction under appropriate supervision
• Cognitive restructuring
• Address comorbid illness
• Limited medication treatment when appropriate

Clinical Pearl: Sleep hygiene alone is usually less effective than a complete CBT-I program.

NPLEX Trap: Do not prescribe sedatives before assessing for sleep apnea, substance use, falls, pregnancy, and medication interactions.

Reference basis: The American College of Physicians recommends CBT-I as initial treatment for chronic insomnia disorder.

Key differentials

• Hyperthyroidism
• Medication or stimulant effects
• Major depression
• Bipolar disorder
• Panic disorder
• Obsessive-compulsive disorder

• Trauma-related disorder
• Substance withdrawal

Treatment principles

• Education and shared decision-making
• Low- or high-intensity CBT according to severity
• SSRI or SNRI when appropriate
• Sleep, exercise, and substance-use support
• Regular outcome monitoring
• Specialist care for severe or treatment-resistant illness

Clinical Pearl: Physical symptoms such as muscle tension and gastrointestinal distress may dominate the presentation.

NPLEX Trap: Benzodiazepines are not preferred as routine long-term treatment for GAD.

Reference basis: NICE recommends stepped care using the least intrusive effective intervention, with psychological treatment and pharmacotherapy selected according to severity and response.

Treatment principles

• Ask about tobacco use
• Advise cessation clearly
• Assess readiness and dependence
• Offer medication and counselling
• Establish a quit plan
• Arrange follow-up
• Normalize repeated quit attempts
• Address household exposure

Clinical Pearl: A lapse does not mean treatment has failed; the plan should be revised and continued.

NPLEX Trap: “Natural” or herbal cigarettes still expose the lungs to harmful combustion products.

Reference basis: The 2025 Canadian Task Force recommends encouraging every person who smokes to stop and offering one or more evidence-based cessation interventions.

Key assessments

• Weight history
• Eating pattern
• Sleep
• Mental health

• Medications promoting weight gain
• Cardiometabolic complications
• Mechanical complications
• Readiness and patient priorities

Treatment principles

• Nutrition treatment
• Physical activity adapted to ability
• Behavioural and psychological support
• Pharmacotherapy
• Bariatric surgery assessment when appropriate
• Long-term follow-up
• Focus on health, function, and quality of life

Clinical Pearl: Weight regain after treatment reflects chronic biological regulation and does not prove a lack of effort.

NPLEX Trap: Do not prescribe unregulated compounded or stimulant products as substitutes for approved obesity treatment.

Key differentials

• Septic arthritis
• Calcium-pyrophosphate disease
• Cellulitis
• Trauma
• Psoriatic arthritis
• Rheumatoid arthritis

Treatment principles

• Treat acute flares with an appropriate anti-inflammatory agent
• Initiate urate-lowering treatment when indicated
• Use flare prophylaxis during initiation when appropriate
• Review alcohol, diet, medications, kidney disease, and cardiovascular risk
• Monitor serum urate and adherence
• Reduce tophus burden and prevent joint damage

Integrative care: Tart-cherry products may be discussed as a dietary adjunct, but they do not replace urate-lowering medication in recurrent tophaceous gout.

Clinical Pearl: Serum urate can fall during an acute attack.

NPLEX Trap: Do not exclude septic arthritis solely because the patient has a history of gout.

Reference basis: NIH guidance identifies crystal deposition as the cause of gout and emphasizes acute-flare control, prevention of future flares, treatment of hyperuricemia, and management of kidney and cardiovascular comorbidity.

Key differentials

• Hypothyroidism
• Inflammatory arthritis
• Polymyalgia rheumatica
• Inflammatory myopathy
• Neurologic disease
• Sleep apnea
• Medication effects
• Major depression

Treatment principles

• Validate the condition
• Education regarding pain processing
• Graded physical activity
• Sleep assessment and treatment
• Cognitive behavioural strategies
• Treatment of mood disorders
• Symptom-directed medication
• Avoid chronic opioid dependence

Physical medicine: Gentle mobility, pacing, and appropriately dosed manual therapy may support function, but aggressive treatment can provoke symptom flares.

Clinical Pearl: Normal inflammatory markers are expected and do not invalidate the patient’s symptoms.

NPLEX Trap: Do not repeatedly order extensive autoimmune testing when the clinical presentation remains stable and no inflammatory features are present.

Reference basis: The American College of Rheumatology and NIH describe fibromyalgia as chronic widespread pain associated with fatigue, sleep disturbance, and altered nervous-system pain processing rather than inflammatory or autoimmune joint disease.

Diagnosis: Chronic plaque psoriasis

Key differentials

• Atopic dermatitis
• Seborrheic dermatitis
• Tinea corporis
• Lichen planus
• Cutaneous T-cell lymphoma

Key assessments

• Body-surface area
• Scalp, nail, genital, palm, and sole involvement
• Joint symptoms
• Effect on quality of life
• Cardiometabolic risk
• Medication and supplement use

Treatment principles

• Moisturizers
• Topical corticosteroids
• Vitamin D analogues
• Phototherapy
• Systemic nonbiologic treatment
• Biologic treatment for appropriate moderate-to-severe disease
• Screening for psoriatic arthritis

Nutrition and lifestyle

• Smoking cessation
• Moderation of alcohol

• Weight and cardiovascular-risk management
• Avoidance of individual triggers when identified

Clinical Pearl: A small involved body-surface area can still represent severe disease when the hands, feet, face, genitals, or nails are affected.

NPLEX Trap: Do not treat chronic psoriasis with prolonged systemic corticosteroid monotherapy.

Reference basis: AAD psoriasis guidance supports topical treatment for limited disease and phototherapy or systemic treatment based on severity, affected sites, comorbidities, and treatment response.

Diagnosis: Early seropositive rheumatoid arthritis

Key differentials

• Psoriatic arthritis
• Systemic lupus erythematosus
• Viral polyarthritis
• Osteoarthritis
• Crystal arthritis
• Reactive arthritis

Key investigations

• CBC
• ESR and CRP
• Rheumatoid factor
• Anti-CCP antibodies
• Renal and liver function
• Baseline radiographs or ultrasound when appropriate
• Hepatitis and tuberculosis assessment before selected immunosuppressive treatments

Treatment principles

• Early rheumatology involvement
• Treat-to-target strategy
• DMARD therapy
• Short-term bridging corticosteroid only when appropriate
• Vaccination and infection-risk assessment
• Exercise and rehabilitation
• Cardiovascular-risk management

Integrative care: Exercise, resistance training, smoking cessation, sleep support, and a balanced dietary pattern may improve general health but do not replace DMARD therapy.

Clinical Pearl: Anti-CCP antibodies are strongly associated with rheumatoid arthritis and may indicate increased risk of erosive disease.

NPLEX Trap: Symptom improvement with an NSAID does not prevent structural joint destruction.

Reference basis: ACR guidance supports early DMARD treatment and a coordinated approach combining pharmacologic treatment, exercise, rehabilitation, vaccination, and comorbidity management.

Key assessments

• Volume status
• Blood pressure and heart rate
• Kidney function and electrolytes
• Medication adherence
• Functional status
• Ischemic and valvular causes
• Arrhythmias
• Iron deficiency
• Sleep apnea

Treatment principles

• Four foundational HFrEF medication classes
• Diuretics for congestion
• Cardiac rehabilitation and regular activity
• Daily symptom and weight monitoring

• Vaccination
• Device therapy when criteria are met
• Advanced-heart-failure referral when appropriate

Botanical safety

• Licorice may cause sodium retention, hypertension, and hypokalemia.
• Hawthorn may interact with cardiovascular medications.
• Herbal diuretics do not replace prescribed diuretic therapy.

Clinical Pearl: Diuretics improve congestion but do not replace disease-modifying HFrEF medications.

NPLEX Trap: Do not begin or rapidly increase a beta-blocker during severe acute fluid-overloaded decompensation without appropriate stabilization.

Reference basis: The AHA/ACC/HFSA heart-failure guideline identifies four foundational medication classes for HFrEF and emphasizes multidisciplinary care and treatment of comorbidities.

Key investigations

• ECG
• CBC
• Electrolytes
• Kidney and liver function
• TSH
• Echocardiography
• Assessment for ischemia or structural disease when appropriate

Treatment principles

• Stroke prevention
• Rate control
• Rhythm control for selected patients
• Management of hypertension, obesity, sleep apnea, diabetes, and alcohol use
• Reassessment as risks and symptoms change

Clinical Pearl: Paroxysmal atrial fibrillation still carries stroke risk.

NPLEX Trap: Do not use aspirin as a routine substitute for indicated anticoagulation.

Reference basis: Current atrial-fibrillation guidance emphasizes risk-factor treatment, stroke prevention, appropriate rate or rhythm control, and ongoing reassessment.

Key differentials

• Lumbar spinal stenosis
• Chronic venous disease
• Musculoskeletal pain
• Peripheral neuropathy
• Deep-vein thrombosis

Red flags for limb-threatening ischemia

• Ischemic rest pain
• Nonhealing ulcer
• Gangrene
• Rapid tissue loss
• Markedly reduced perfusion

Treatment principles

• Smoking cessation
• Antiplatelet therapy
• High-intensity lipid treatment
• Diabetes and blood-pressure management
• Structured exercise
• Foot care
• Revascularization for selected patients

Clinical Pearl: PAD is a marker of systemic atherosclerosis and increased myocardial-infarction and stroke risk.

NPLEX Trap: Do not apply strong compression to an ischemic leg before assessing arterial circulation.

Reference basis: The 2024 multisociety PAD guideline addresses asymptomatic PAD, chronic symptomatic PAD, chronic limb-threatening ischemia, and acute limb ischemia.

Potential complications

• Stasis dermatitis
• Lipodermatosclerosis
• Venous ulceration
• Recurrent superficial thrombophlebitis
• Secondary infection

Treatment principles

• Compression when appropriate
• Exercise and calf-muscle activation
• Leg elevation
• Weight and mobility management
• Skin care
• Venous-ulcer care
• Endovenous or surgical intervention in selected patients

Botanical safety: Horse-chestnut preparations have variable quality and may interact with anticoagulants. They should not replace compression, ulcer care, or vascular assessment.

Clinical Pearl: Venous ulcers commonly occur near the medial malleolus.

NPLEX Trap: Bilateral chronic edema with pigmentation is not automatically heart failure or acute DVT.

Reference basis: Vascular guidelines support duplex evaluation, compression, exercise, skin care, and intervention according to venous anatomy, symptoms, ulceration, and arterial status.

Potential complications

• Upper-GI bleeding
• Perforation
• Gastric-outlet obstruction
• Iron-deficiency anemia
• Gastric adenocarcinoma
• Gastric lymphoma

Key investigations

• Urea breath test
• Stool antigen test
• Endoscopy for alarm symptoms or appropriate risk groups
• CBC when anemia or bleeding is suspected

• Medication review, especially NSAIDs

Treatment principles

• Eradicate H. pylori
• Confirm cure
• Stop unnecessary NSAIDs
• Assess alarm symptoms
• Investigate persistent symptoms

NPLEX Trap: Improvement in pain does not prove eradication.

Reference basis: The 2024 ACG guideline recommends effective resistance-conscious eradication therapy and universal confirmation of cure after treatment.

Potential manifestations

• Diarrhea
• Constipation
• Abdominal pain
• Iron deficiency
• Osteoporosis
• Dermatitis herpetiformis
• Neurologic symptoms
• Infertility
• Abnormal liver enzymes

Key investigations

• tTG-IgA and total IgA
• Alternative IgG-based testing when appropriate
• Duodenal biopsy
• CBC and ferritin
• Folate and vitamin B12
• Vitamin D
• Calcium
• Bone-density assessment when indicated

Nutrition principles

• Dietitian-supported gluten-free diet
• Correct nutritional deficiencies
• Use certified gluten-free oats when tolerated
• Avoid unnecessary restrictive diets

Clinical Pearl: Celiac disease can present without diarrhea.

NPLEX Trap: Food-IgG testing does not diagnose celiac disease.

Reference basis: ACG guidance recommends testing while the patient is consuming gluten, appropriate serology, confirmatory biopsy in most adults, and lifelong gluten avoidance after diagnosis.

Key investigations

• HBeAg and anti-HBe
• Quantitative HBV DNA

• ALT and AST
• Bilirubin and albumin
• INR
• CBC and platelets
• Fibrosis assessment
• Kidney function before selected antivirals
• Hepatitis D testing when indicated
• Hepatocellular-carcinoma surveillance in appropriate risk groups

Treatment principles

• Phase and fibrosis assessment
• Antiviral therapy when indicated
• Long-term adherence
• Monitoring for treatment response
• HCC surveillance according to risk
• Vaccination of contacts
• Avoidance of excess alcohol and hepatotoxic products

Botanical safety: Kava, concentrated green-tea extracts, comfrey, and poorly characterized multi-herb products may cause liver injury.

Clinical Pearl: A normal ALT does not automatically mean chronic hepatitis B is harmless.

NPLEX Trap: Do not stop long-term HBV antiviral therapy abruptly without specialist guidance because severe reactivation can occur.

Reference basis: Updated AASLD and WHO guidance emphasizes simplified treatment eligibility, fibrosis assessment, antiviral treatment, transmission prevention, HDV testing, and liver-cancer surveillance.